NCT00093028View on ClinicalTrials.gov

Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II

PHASE3CompletedINTERVENTIONAL
Enrollment

315

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Multiple Myeloma
Interventions
DRUG

CC-5013 (Revlimid™)

N/A Study Complete

DRUG

bortezomib

N/A Study Complete

Trial Locations (1)

72205

University of Arkansas for Medical Sciences/MIRT, Little Rock

All Listed Sponsors
lead

University of Arkansas

OTHER

NCT00093028 - Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II | Biotech Hunter | Biotech Hunter